goserelin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
pituitary hormone-release stimulating peptides	1327	65807-02-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: goserelin Decapeptide I zoladex goserelin acetate	A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer. Molecular weight: 1269.43 Formula: C59H84N18O14 CLOGP: -5.05 LIPINSKI: 3 HAC: 32 HDO: 18 TPSA: 493.39 ALOGS: -4.48 ROTB: 33

Molecule

Description

Molfile Inchi Smiles

Synonyms:

goserelin
Decapeptide I
zoladex
goserelin acetate

A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.

Molecular weight: 1269.43
Formula: C59H84N18O14
CLOGP: -5.05
LIPINSKI: 3
HAC: 32
HDO: 18
TPSA: 493.39
ALOGS: -4.48
ROTB: 33

Drug dosage:

Dose	Unit	Route
0.13	mg	implant

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	20 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Dec. 29, 1989	FDA	ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	844.23	19.42	359	9896	81762	63397005
Metastases to bone	813.91	19.42	246	10009	20773	63457994
Metastases to liver	665.75	19.42	217	10038	23422	63455345
Neutropenia	350.09	19.42	261	9994	174744	63304023
Neoplasm progression	195.32	19.42	102	10153	36326	63442441
PIK3CA-activated mutation	172.99	19.42	39	10216	1020	63477747
Metastases to lung	172.07	19.42	68	10187	12682	63466085
Metastases to lymph nodes	155.43	19.42	56	10199	8102	63470665
Tumour marker increased	137.58	19.42	45	10210	4870	63473897
Bone lesion	137.43	19.42	47	10208	5834	63472933
Breast cancer metastatic	134.36	19.42	56	10199	11962	63466805
Metastases to skin	121.29	19.42	32	10223	1631	63477136
Disease progression	118.18	19.42	121	10134	122637	63356130
Breast cancer	116.49	19.42	81	10174	48302	63430465
Hot flush	107.86	19.42	79	10176	51080	63427687
Metastases to central nervous system	107.18	19.42	49	10206	13056	63465711
Abdominal lymphadenopathy	97.96	19.42	23	10232	722	63478045
Metastases to spine	87.91	19.42	29	10226	3220	63475547
Bone disorder	81.99	19.42	48	10207	21278	63457489
Metastases to peritoneum	78.43	19.42	27	10228	3415	63475352
Metastases to spinal cord	70.30	19.42	13	10242	120	63478647
Drug ineffective	69.14	19.42	42	10213	1044723	62434044
Invasive lobular breast carcinoma	69.00	19.42	18	10237	877	63477890
Lymphadenopathy	66.94	19.42	53	10202	38405	63440362
Neuropathy peripheral	65.38	19.42	86	10169	113581	63365186
Jaundice	63.50	19.42	46	10209	29205	63449562
Ascites	60.12	19.42	51	10204	40677	63438090
Metastases to pleura	58.82	19.42	18	10237	1567	63477200
Metastases to nervous system	57.31	19.42	10	10245	64	63478703
Carbohydrate antigen 15-3 increased	56.11	19.42	17	10238	1431	63477336
Breast cancer recurrent	54.54	19.42	22	10233	4319	63474448
Osteonecrosis of jaw	53.94	19.42	45	10210	35078	63443689
Osteolysis	48.32	19.42	18	10237	2856	63475911
Pleural neoplasm	46.40	19.42	11	10244	360	63478407
Pneumonitis	45.73	19.42	41	10214	35181	63443586
Pleural effusion	43.79	19.42	64	10191	93146	63385621
Carcinoid tumour pulmonary	43.63	19.42	11	10244	467	63478300
CYP3A4 polymorphism	42.68	19.42	8	10247	80	63478687
Invasive ductal breast carcinoma	41.63	19.42	21	10234	6937	63471830
Metastases to adrenals	38.51	19.42	11	10244	754	63478013
Neutrophil count decreased	37.66	19.42	46	10209	56360	63422407
Adnexa uteri mass	36.92	19.42	10	10245	563	63478204
Osteonecrosis	36.77	19.42	31	10224	24499	63454268
Bone pain	35.57	19.42	44	10211	54597	63424170
Osteitis condensans	35.48	19.42	6	10249	31	63478736
Leukopenia	34.75	19.42	52	10203	77238	63401529
Lymphadenopathy mediastinal	34.48	19.42	14	10241	2794	63475973
Breast mass	33.56	19.42	19	10236	7903	63470864
Merycism	33.42	19.42	8	10247	273	63478494
Hepatic lesion	33.14	19.42	16	10239	4809	63473958
Endometrial hyperplasia	32.68	19.42	10	10245	870	63477897
Oestradiol abnormal	32.58	19.42	6	10249	54	63478713
White blood cell count decreased	32.13	19.42	70	10185	139034	63339733
Alanine aminotransferase increased	32.10	19.42	59	10196	103711	63375056
Fibrous histiocytoma	32.08	19.42	9	10246	578	63478189
Metastasis	32.01	19.42	16	10239	5181	63473586
Metastatic neoplasm	31.81	19.42	15	10240	4280	63474487
Spinal pain	31.59	19.42	22	10233	13117	63465650
Aspartate aminotransferase increased	31.36	19.42	54	10201	90223	63388544
Pleural disorder	31.21	19.42	9	10246	638	63478129
Tumour flare	30.86	19.42	8	10247	380	63478387
Dermatitis	30.85	19.42	24	10231	16934	63461833
Bone marrow infiltration	30.72	19.42	9	10246	675	63478092
Mucinous breast carcinoma	29.87	19.42	5	10250	24	63478743
Oestradiol increased	29.71	19.42	6	10249	91	63478676
Condition aggravated	29.61	19.42	14	10241	402203	63076564
Selenium deficiency	29.54	19.42	5	10250	26	63478741
Arachnoid cyst	29.53	19.42	7	10248	229	63478538
Drug hypersensitivity	29.49	19.42	7	10248	310680	63168087
Mood swings	29.30	19.42	24	10231	18224	63460543
Metastases to the mediastinum	29.04	19.42	8	10247	480	63478287
Uterine mass	27.70	19.42	7	10248	300	63478467
Body surface area increased	27.35	19.42	5	10250	43	63478724
Pathological fracture	26.56	19.42	17	10238	8817	63469950
Breast cancer female	26.44	19.42	20	10235	13539	63465228
Gamma-glutamyltransferase increased	26.44	19.42	30	10225	34001	63444766
Palmar-plantar erythrodysaesthesia syndrome	26.39	19.42	25	10230	22990	63455777
Central nervous system lesion	26.02	19.42	18	10237	10617	63468150
Febrile neutropenia	25.53	19.42	58	10197	118391	63360376
Arthropathy	24.98	19.42	4	10251	234788	63243979
Metastases to ovary	24.93	19.42	7	10248	451	63478316
Mucosal inflammation	24.64	19.42	34	10221	46894	63431873
Metastases to stomach	24.49	19.42	6	10249	226	63478541
Uterine polyp	24.41	19.42	10	10245	2040	63476727
Hepatotoxicity	24.38	19.42	30	10225	37011	63441756
Cervical polyp	24.29	19.42	6	10249	234	63478533
Uterine leiomyoma	23.52	19.42	16	10239	9182	63469585
Musculoskeletal chest pain	22.47	19.42	22	10233	21061	63457706
Amenorrhoea	22.44	19.42	16	10239	9898	63468869
Hepatic cancer	22.41	19.42	12	10243	4475	63474292
Hypersensitivity	21.81	19.42	10	10245	292675	63186092
Ocular icterus	21.77	19.42	11	10244	3645	63475122
Bile duct stenosis	21.60	19.42	8	10247	1248	63477519
Depressed mood	20.92	19.42	29	10226	40162	63438605
Blood alkaline phosphatase increased	20.88	19.42	30	10225	42937	63435830
Hepatic cyst	20.86	19.42	12	10243	5142	63473625
Disturbance in attention	20.55	19.42	28	10227	38161	63440606
Lymphangioleiomyomatosis	20.45	19.42	5	10250	187	63478580
Metastases to pelvis	20.28	19.42	6	10249	465	63478302
Acute promyelocytic leukaemia	20.07	19.42	7	10248	920	63477847
Tooth extraction	19.70	19.42	15	10240	10249	63468518
Cholangitis sclerosing	19.53	19.42	8	10247	1633	63477134

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis of jaw	288.37	15.33	129	10266	17760	34928776
Prostatic specific antigen increased	240.18	15.33	107	10288	14573	34931963
Metastases to bone	220.97	15.33	95	10300	11875	34934661
Malignant neoplasm progression	167.72	15.33	166	10229	87880	34858656
Prostate cancer metastatic	144.23	15.33	57	10338	5746	34940790
Hot flush	110.16	15.33	68	10327	17998	34928538
Interstitial lung disease	104.12	15.33	112	10283	65170	34881366
Osteonecrosis	103.58	15.33	61	10334	14829	34931707
Prostate cancer	79.49	15.33	77	10318	39572	34906964
Malignant spinal cord compression	60.24	15.33	13	10382	144	34946392
Osteomyelitis	56.17	15.33	43	10352	16093	34930443
Haematuria	50.31	15.33	68	10327	49998	34896538
Death	48.73	15.33	240	10155	397809	34548727
Tooth extraction	48.39	15.33	25	10370	4703	34941833
Osteitis	44.24	15.33	17	10378	1587	34944949
Pain in jaw	39.45	15.33	32	10363	13008	34933528
Bone pain	37.40	15.33	38	10357	20648	34925888
Central nervous system mass	37.23	15.33	9	10386	170	34946366
Wall motion score index abnormal	37.08	15.33	9	10386	173	34946363
Blood testosterone increased	36.93	15.33	14	10381	1259	34945277
Pituitary haemorrhage	36.24	15.33	9	10386	191	34946345
Airway remodelling	34.65	15.33	9	10386	230	34946306
Bone disorder	34.36	15.33	22	10373	6193	34940343
Atopy	34.17	15.33	9	10386	243	34946293
Pituitary tumour benign	34.16	15.33	12	10383	869	34945667
Exposed bone in jaw	33.95	15.33	14	10381	1572	34944964
Cancer pain	32.85	15.33	16	10379	2656	34943880
Hepatic function abnormal	32.59	15.33	52	10343	44311	34902225
Hypocalcaemia	32.36	15.33	38	10357	24251	34922285
Cardiac septal defect	32.07	15.33	9	10386	310	34946226
Metastases to spine	30.35	15.33	15	10380	2569	34943967
Contracted bladder	28.94	15.33	5	10390	14	34946522
Eosinophilic myocarditis	27.21	15.33	9	10386	543	34945993
Device expulsion	26.78	15.33	6	10389	80	34946456
Eosinophilic cystitis	26.03	15.33	5	10390	29	34946507
PO2 increased	25.94	15.33	9	10386	628	34945908
Drug ineffective	25.47	15.33	62	10333	456689	34489847
Gingival erythema	24.89	15.33	6	10389	112	34946424
Metastases to lymph nodes	24.33	15.33	16	10379	4712	34941824
Toxicity to various agents	23.99	15.33	15	10380	200347	34746189
Haemoglobin decreased	23.40	15.33	84	10311	120688	34825848
Purulent discharge	23.30	15.33	13	10382	2850	34943686
Gingivitis	23.16	15.33	14	10381	3561	34942975
Ubiquinone decreased	22.94	15.33	4	10391	12	34946524
Bone sequestrum	22.84	15.33	8	10387	574	34945962
Microangiopathy	22.40	15.33	9	10386	945	34945591
Urinary retention	21.94	15.33	39	10356	36249	34910287
Bone debridement	21.57	15.33	6	10389	200	34946336
Injection site haemorrhage	21.51	15.33	20	10375	9748	34936788
Arterial injury	21.10	15.33	7	10388	426	34946110
Eosinophilic pneumonia	20.87	15.33	13	10382	3488	34943048
Blood alkaline phosphatase increased	20.80	15.33	35	10360	31140	34915396
Sequestrectomy	20.79	15.33	6	10389	229	34946307
Bone lesion	20.23	15.33	12	10383	2951	34943585
PCO2 decreased	19.94	15.33	10	10385	1766	34944770
Injection site haematoma	19.90	15.33	10	10385	1775	34944761
Respiratory symptom	19.83	15.33	10	10385	1787	34944749
Terminal state	19.48	15.33	13	10382	3921	34942615
Pulmonary embolism	18.74	15.33	64	10331	89682	34856854
Hypophosphataemia	17.67	15.33	19	10376	11007	34935529
Spinal cord compression	17	15.33	12	10383	3963	34942573
Gingival swelling	16.87	15.33	8	10387	1252	34945284
Blood immunoglobulin E increased	16.57	15.33	10	10385	2536	34944000
Metastasis	16.55	15.33	12	10383	4132	34942404
Protein total decreased	16.39	15.33	13	10382	5117	34941419
Off label use	16.27	15.33	67	10328	419457	34527079
Eosinophilic granulomatosis with polyangiitis	16.11	15.33	9	10386	1978	34944558
Metastases to liver	15.95	15.33	20	10375	13643	34932893
Back pain	15.89	15.33	75	10320	121714	34824822
Breast cancer	15.41	15.33	5	10390	284	34946252

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metastases to bone	652.24	14.96	230	16450	24197	79703511
Malignant neoplasm progression	517.49	14.96	333	16347	135657	79592051
Metastases to liver	377.38	14.96	161	16519	28153	79699555
Osteonecrosis of jaw	250.39	14.96	139	16541	43087	79684621
Neutropenia	213.68	14.96	281	16399	287429	79440279
Prostatic specific antigen increased	175.40	14.96	70	16610	10316	79717392
Hot flush	152.64	14.96	111	16569	54766	79672942
Metastases to lymph nodes	148.00	14.96	62	16618	10335	79717373
Prostate cancer metastatic	123.29	14.96	42	16638	3965	79723743
Metastases to lung	112.24	14.96	61	16619	18102	79709606
Neoplasm progression	109.62	14.96	89	16591	51593	79676115
PIK3CA-activated mutation	102.11	14.96	24	16656	579	79727129
Bone lesion	100.30	14.96	40	16640	5879	79721829
Osteonecrosis	86.65	14.96	63	16617	31032	79696676
Drug ineffective	77.15	14.96	68	16612	1080845	78646863
Prostate cancer	74.16	14.96	59	16621	33209	79694499
Interstitial lung disease	72.72	14.96	103	16577	112497	79615211
Breast mass	72.43	14.96	33	16647	6721	79720987
Breast cancer metastatic	67.76	14.96	34	16646	8568	79719140
Malignant spinal cord compression	64.63	14.96	13	16667	146	79727562
Metastases to spine	62.25	14.96	26	16654	4298	79723410
Metastases to central nervous system	61.78	14.96	40	16640	16335	79711373
Abdominal lymphadenopathy	61.49	14.96	19	16661	1315	79726393
Disease progression	57.28	14.96	122	16558	184240	79543468
Metastases to skin	56.53	14.96	19	16661	1720	79725988
Bone pain	55.02	14.96	63	16617	55679	79672029
Osteolysis	54.69	14.96	24	16656	4474	79723234
Tumour marker increased	52.61	14.96	23	16657	4249	79723459
Carbohydrate antigen 15-3 increased	51.02	14.96	16	16664	1163	79726545
Bone disorder	47.15	14.96	36	16644	19077	79708631
Breast cancer	45.42	14.96	45	16635	33736	79693972
Lymphadenopathy	42.44	14.96	54	16626	53193	79674515
Death	42.08	14.96	231	16449	566283	79161425
Wall motion score index abnormal	40.23	14.96	9	16671	173	79727535
Central nervous system mass	40.18	14.96	9	16671	174	79727534
Breast cancer recurrent	39.85	14.96	17	16663	2960	79724748
Tooth extraction	39.37	14.96	26	16654	10969	79716739
Adnexa uteri mass	38.07	14.96	10	16670	384	79727324
Infusion related reaction	36.89	14.96	3	16677	230234	79497474
Invasive lobular breast carcinoma	36.49	14.96	11	16669	700	79727008
Blood alkaline phosphatase increased	36.38	14.96	55	16625	63609	79664099
Airway remodelling	35.94	14.96	9	16671	285	79727423
Haematuria	35.88	14.96	57	16623	68779	79658929
CYP3A4 polymorphism	35.54	14.96	7	16673	70	79727638
Pituitary haemorrhage	35.44	14.96	9	16671	302	79727406
Mucinous breast carcinoma	34.80	14.96	6	16674	26	79727682
Cardiac septal defect	34.59	14.96	9	16671	333	79727375
Osteitis condensans	33.93	14.96	6	16674	31	79727677
Osteomyelitis	33.88	14.96	38	16642	32827	79694881
Atopy	32.34	14.96	9	16671	431	79727277
Osteitis	32.28	14.96	16	16664	3927	79723781
Merycism	31.86	14.96	8	16672	256	79727452
Spinal pain	31.55	14.96	26	16654	15366	79712342
Pathological fracture	30.83	14.96	22	16658	10515	79717193
Metastases to peritoneum	30.71	14.96	16	16664	4356	79723352
Completed suicide	30.51	14.96	7	16673	245760	79481948
Rheumatoid arthritis	30.10	14.96	4	16676	208466	79519242
Hepatic function abnormal	29.47	14.96	54	16626	73053	79654655
Endometrial hyperplasia	29.07	14.96	9	16671	627	79727081
Contracted bladder	28.76	14.96	5	16675	23	79727685
Hepatic lesion	28.73	14.96	18	16662	6941	79720767
Blood testosterone increased	28.39	14.96	10	16670	1042	79726666
Fibrous histiocytoma	27.98	14.96	9	16671	710	79726998
Selenium deficiency	27.10	14.96	5	16675	34	79727674
Arthropathy	26.54	14.96	3	16677	177108	79550600
Metastasis	26.42	14.96	17	16663	6863	79720845
Dental fistula	26.31	14.96	8	16672	524	79727184
Drug hypersensitivity	26.18	14.96	15	16665	298901	79428807
Cancer pain	25.33	14.96	15	16665	5230	79722478
Pleural disorder	25.31	14.96	9	16671	964	79726744
Metastases to spinal cord	25.30	14.96	5	16675	51	79727657
Metastases to the mediastinum	25.24	14.96	8	16672	602	79727106
Cervical polyp	25.13	14.96	6	16674	155	79727553
Lymphadenopathy mediastinal	25.05	14.96	14	16666	4382	79723326
Arachnoid cyst	24.96	14.96	7	16673	345	79727363
Metastases to meninges	24.79	14.96	13	16667	3588	79724120
White blood cell count decreased	24.68	14.96	91	16589	188197	79539511
Pleural neoplasm	24.65	14.96	7	16673	361	79727347
Neuropathy peripheral	24.46	14.96	75	16605	141230	79586478
Carcinoid tumour pulmonary	24.36	14.96	7	16673	377	79727331
Pulmonary embolism	23.37	14.96	84	16596	171570	79556138
Eosinophilic myocarditis	23.31	14.96	9	16671	1213	79726495
Bone sequestrum	23.26	14.96	9	16671	1220	79726488
Bone debridement	23.18	14.96	7	16673	448	79727260
Hypocalcaemia	22.86	14.96	39	16641	49885	79677823
Toxicity to various agents	22.83	14.96	33	16647	421507	79306201
Pituitary tumour benign	22.72	14.96	11	16669	2565	79725143
Alanine aminotransferase increased	22.51	14.96	80	16600	162490	79565218
Pneumonitis	22.10	14.96	43	16637	60817	79666891
Eosinophilic cystitis	21.93	14.96	5	16675	105	79727603
Hypersensitivity	21.78	14.96	14	16666	262225	79465483
Ubiquinone decreased	21.46	14.96	4	16676	29	79727679
Pleural effusion	21.43	14.96	73	16607	145189	79582519
Respiratory symptom	21.32	14.96	13	16667	4778	79722930
Metastases to pleura	21.22	14.96	9	16671	1545	79726163
Uterine polyp	21.05	14.96	9	16671	1575	79726133
PO2 increased	21.03	14.96	9	16671	1579	79726129
BRCA1 gene mutation	21.00	14.96	4	16676	33	79727675
Jaundice	20.98	14.96	39	16641	53310	79674398
Metastases to pelvis	20.60	14.96	7	16673	655	79727053
Electrocardiogram QT prolonged	20.57	14.96	53	16627	90333	79637375
Febrile neutropenia	20.41	14.96	99	16581	230900	79496808
Body surface area increased	20.36	14.96	5	16675	146	79727562
Oestradiol abnormal	20.22	14.96	4	16676	41	79727667
Gingivitis	20.10	14.96	16	16664	9005	79718703
Lymphangioleiomyomatosis	19.68	14.96	5	16675	168	79727540
Ocular icterus	19.68	14.96	13	16667	5487	79722221
Microangiopathy	19.64	14.96	9	16671	1856	79725852
Haemoglobin decreased	19.48	14.96	95	16585	222024	79505684
Neutrophil count decreased	19.27	14.96	53	16627	93906	79633802
Nasopharyngitis	19.18	14.96	15	16665	253866	79473842
Prostate cancer recurrent	19.15	14.96	7	16673	811	79726897
Exposed bone in jaw	18.92	14.96	11	16669	3709	79723999
Breast swelling	18.87	14.96	8	16672	1372	79726336
Mood swings	18.82	14.96	22	16658	19858	79707850
Metastases to nervous system	18.46	14.96	4	16676	66	79727642
Sinusitis	18.30	14.96	9	16671	195492	79532216
Decreased appetite	18.04	14.96	128	16552	342290	79385418
Application site haematoma	18.03	14.96	4	16676	74	79727634
Overdose	17.98	14.96	8	16672	184198	79543510
Gamma-glutamyltransferase increased	17.90	14.96	37	16643	54643	79673065
PCO2 decreased	17.85	14.96	10	16670	3144	79724564
Libido decreased	17.65	14.96	12	16668	5309	79722399
Breast injury	17.59	14.96	4	16676	83	79727625
Leukopenia	17.57	14.96	59	16621	116454	79611254
Lymphoedema	17.55	14.96	17	16663	12396	79715312
Joint swelling	17.25	14.96	21	16659	288625	79439083
Breast pain	17.02	14.96	14	16666	8251	79719457
Oestradiol increased	16.77	14.96	4	16676	103	79727605
Central nervous system lesion	16.49	14.96	17	16663	13351	79714357
Musculoskeletal chest pain	16.48	14.96	23	16657	24741	79702967
Menopausal symptoms	16.17	14.96	8	16672	1955	79725753
Amenorrhoea	15.78	14.96	13	16667	7679	79720029
Uterine leiomyoma	15.59	14.96	12	16668	6431	79721277
Bone trimming	15.52	14.96	3	16677	27	79727681
Platelet count decreased	15.48	14.96	81	16599	194583	79533125
Eosinophilic pneumonia	15.34	14.96	11	16669	5299	79722409
Acute promyelocytic leukaemia	15.09	14.96	7	16673	1484	79726224
Condition aggravated	15.08	14.96	54	16626	501070	79226638

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L02AE03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Gonadotropin releasing hormone analogues
FDA MoA	N0000175654	Gonadotropin Releasing Hormone Receptor Agonists
FDA EPC	N0000175655	Gonadotropin Releasing Hormone Receptor Agonist
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018931	Antineoplastic Agents, Hormonal

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Endometriosis	indication	129103003
Hormone receptor positive malignant neoplasm of breast	indication	417181009
Advanced Prostatic Carcinoma	indication
Endometrial Ablation Adjunct	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Hypercholesterolemia	contraindication	13644009
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypercalcemia	contraindication	66931009	DOID:12678
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Pregnancy, function	contraindication	289908002
Bilateral orchidectomy	contraindication	386634006
Cardiovascular event risk	contraindication	395112001
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Smokes tobacco daily	contraindication	449868002
Bone Metastases	contraindication
Vertebral Metastases	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.85	acidic
pKa2	9.65	acidic
pKa3	11.9	acidic
pKa4	12.55	acidic
pKa5	13.03	acidic
pKa6	13.27	acidic
pKa7	13.43	acidic
pKa8	10.75	Basic
pKa9	6.69	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Gonadotropin-releasing hormone receptor	GPCR	P30968	GNRHR_HUMAN	AGONIST				CHEMBL	CHEMBL
Lutropin-choriogonadotropic hormone receptor	GPCR	P22888	LSHR_HUMAN					WOMBAT-PK

External reference:

ID	Source
N0000007256	NUI
D00573	KEGG_DRUG
145781-92-6	SECONDARY_CAS_RN
4019508	VANDF
C0120107	UMLSCUI
CHEBI:5523	CHEBI
CHEMBL1201247	ChEMBL_ID
CHEMBL1200501	ChEMBL_ID
D017273	MESH_DESCRIPTOR_UI
DB00014	DRUGBANK_ID
3879	IUPHAR_LIGAND_ID
5943	INN_ID
0F65R8P09N	UNII
5311128	PUBCHEM_CID
203146	RXNORM
1550	MMSL
4799	MMSL
d01354	MMSL
003532	NDDF
006407	NDDF
008308	NDDF
008309	NDDF
108771008	SNOMEDCT_US
108773006	SNOMEDCT_US
126138002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ZOLADEX	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3466	IMPLANT	3.60 mg	SUBCUTANEOUS	NDA	26 sections
ZOLADEX	HUMAN PRESCRIPTION DRUG LABEL	1	70720-950	IMPLANT	3.60 mg	SUBCUTANEOUS	NDA	27 sections
ZOLADEX	HUMAN PRESCRIPTION DRUG LABEL	1	70720-950	IMPLANT	3.60 mg	SUBCUTANEOUS	NDA	27 sections
ZOLADEX	HUMAN PRESCRIPTION DRUG LABEL	1	70720-950	IMPLANT	3.60 mg	SUBCUTANEOUS	NDA	27 sections
ZOLADEX	HUMAN PRESCRIPTION DRUG LABEL	1	70720-951	IMPLANT	10.80 mg	SUBCUTANEOUS	NDA	26 sections
ZOLADEX	HUMAN PRESCRIPTION DRUG LABEL	1	70720-951	IMPLANT	10.80 mg	SUBCUTANEOUS	NDA	26 sections